Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06565689
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-19
Brief Title:
A Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of YK012
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Multi-center Open-Label Phase 1 Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of YK012 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to provide a basis for further clinical development of YK012
Detailed Description:
This study is the first-in-human clinical trial to evaluate the safety tolerability pharmacokinetic PK profile and preliminary efficacy of YK012 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma RR B-NHL
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None